We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials
PeriodicalsMedical Sciences

Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials

Checking your access to this record.

Abstract & Overview

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, their oral toxicity profile is not well elucidated. This review aimed to investigate the prevalence of oral toxicities including xerostomia, mucositis/stomatitis, dysgeusia, dysphagia, oral/oropharyngeal pain, oral infections, angular cheilitis, osteonecrosis, osteomyelitis, and oral mucosal reactions with ICIs. A review protocol was registered with PROSPERO (ID: CRD42023391674). A systematic search of ClinicalTrials.gov was conducted as of April 10, 2022. Studies were selected, assessed, and data extracted using PRISMA guidelines. Oral toxicity data were extracted from study arms using a single immunotherapy drug. Meta-analyses were conducted to summarize prevalence of oral toxicities using random-effects models. Of 750 screened records, 95 trials were included in the meta-analysis with published results. Time between study completion and first publication on ClinicalTrials.gov was 1 to 146 months (mean = 20.3, SD = 18.4). Weighted pooled prevalence was 5% (95% CI: 4-6%) for xerostomia, 3% (95% CI: 3-4%) for mucositis/stomatitis, 3% (95% CI: 2-3%) for dysgeusia, 2% (95% CI: 1-2%) for dysphagia, 3% (95% CI: 2-4%) for oropharyngeal/oral pain, 2% (95% CI: 1-3%) for oral candidiasis, and 2% (95% CI: 0-4%) for angular cheilitis. Subgroup differences based on ICI drugs were minimal. No trials reported lichenoid or pemphigoid mucosal reactions. Meta-analysis results revealed low prevalence of oral toxicities with ICIs; however, data reporting was limited and inconsistent. Limitations of study dataset reveal a significant need for systematic collection of oral morbidity data as well as improved consistency and compliance of reporting results on ClinicalTrials.gov.

Cite this record

Akanksha Srivastava, Graciela M. Nogueras‐González, Yimin Geng, Jasdev Singh, Jeffrey N. Myers, Yisheng Li, et al. (2023). Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials. Journal of Immunotherapy and Precision Oncology, 7(1), 24–40. https://doi.org/10.36401/jipo-23-14

Copy in another style

Srivastava, A., Nogueras‐González, G. M., Geng, Y., Singh, J., Myers, J. N., Li, Y., & Chambers, M. S. (2023). Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials. Journal of Immunotherapy and Precision Oncology, 7(1), 24–40. https://doi.org/10.36401/jipo-23-14
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.